RXRX FY 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+10.6% YoY

Gross Profit

$1M2.9% margin

Operating Income

-$350M-797.8% margin

Net Income

-$328M-747.7% margin

EPS (Diluted)

$-1.58

Cash Flow

Operating Cash Flow

-$288M

Free Cash Flow

-$300M

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$654M

Total Liabilities

$190M

Stockholders' Equity

$463M

Cash & Equivalents

$392M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$40M	+10.6%
Gross Profit	$1M	-$9M	+115.0%
Operating Income	-$350M	-$246M	-42.5%
Net Income	-$328M	-$239M	-37.0%